[1] World Health Organization.Global tuberculosis report 2020[EB/OL].(2020-10-27)[2021-03-20].https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2020. [2] Chinese Medical Association.Guidelines for clinical treatment: tuberculosis volume(临床诊疗指南:结核病分册)[M]. Beijing: People's Medical Publishing House, 2005: 65, 80. [3] TAN SY, LI YQ.Application of fluoroquinolones in the treatment of multidrug-resistant tuberculosis[J]. Chinese Journal of Antituberculosis(中国防痨杂志), 2005,27(4): 267-270. [4] Chinese Antituberculosis Association. Chinese Antituberculosis Association(2019)[J]. Chinese Journal of Antituberculosis(中国防痨杂志), 2019, 41(10): 1025-1073. [5] DOOSOO J.WHO treatment guidelines for drug-resistant tuberculosis,2016 update: applicability in South Korea[J]. Tuberculosis & Respiratory Diseases, 2017, 80(4): 336-343. [6] SONG WJ.Clinical analysis of adverse reactions of fluoroquinolones[J]. Chinese Journal of Modern Drug Application(中国现代药物应用),2015, 9(15): 158-159. [7] FAN M.Literature analysis on ADR induced by quinolones in the elderly[J].China Pharmacy(中国药房), 2010, 21(18): 1704-1706. [8] Jiao WW, Sun L, Xiao J, et al.Guidelines for national tuberculosis programmes-management of tuberculosis in children(version 2)[J]. Chinese Journal of Evidence Based Pediatrics(中国循证儿科杂志),2016, 11(1): 65-74. [9] YANG XJ, XIE HT, WANG HF.Analysis of 176 new and severe ADR reports[J]. China Pharmacy(中国药房), 2014, 25(14): 1301-1303. [10] TAN LL.Clinical adverse reactions of quinolone antibacterial drugs[J]. Chinese Journal of Pharmacovigilance(中国药物警戒),2013, 10(2): 92-95. [11] National Medical Products Administration. Adverse drug reactions information bulletin (Issue 58) focuses on serious adverse reactions to fluoroquinolones [EB/OL]. (2013-11-21)[2021-03-14]. https://www.nmpa.gov.cn/directory/web/nmpa/xxgk/yjjsh/ypblfytb/20131121120001488.html. [12] National Medical Products Administration. Notice of the General Administration of the People's Republic of China on the Revision of the instructions for fluoroquinolones for whole body use (No. 79, 2017)[EB/OL]. (2017-07-05)[2021-03-14].https://www.nmpa.gov.cn/directory/web/nmpa/xxgk/ggtg/ypshmshxdgg/20170705171401817.html. [13] CHANG XY, GUO GM.Analysis of literature on adverse reactions to thrombocytopenia induced by quinolones[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2020, 17(4): 227-230. [14] LINDEN PDVD, STURKENBOOM MCJM, HERINGS RMC.et al.Fluoroquinolones and risk of Achilles tendon disorders: case-control study[J]. British Medical Journal, 2002, 324(7349): 1306-1307. [15] SHU CHEN K, YUNG TAI C, YI TZU L, et al.Association between recent use of fluoroquinolones and rhegmatogenous retinal detachment: a population-based cohort study[J]. Clinical Infectious Diseases, 2014, 58(2): 197-203. [16] MEHRZAD R, BARZA M.Weighing the adverse cardiac effects of fluoroquinolones: a risk perspective[J]. Journal of Clinical Pharmacology, 2015, 55(11): 1198-206. [17] LIN X, LI J, REN HL.Analysis of 481 reports of adverse drug reactions induced by quinolone drugs[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2019, 16(10): 617-624. |